Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Pediatric Multiple Sclerosis

  • Pediatric Neurology (RM Boustany, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The past 10 years have borne witness to increased recognition and diagnosis of pediatric multiple sclerosis (MS). Additionally, during this time period, the number of treatment options available for MS patients has increased significantly, as has the number of studies evaluating the use of these therapies in children. Though the U.S. Food and Drug Administration has not formally approved any of these therapies for use in pediatric MS, a number of injectable, oral, and intravenous treatments are currently being used off-label in these children. Disease modifying therapy should be initiated promptly following a diagnosis of MS. The patient and family should be engaged in the choice of therapy as this is likely to promote adherence. First-line options include any of the injectable therapies (glatiramer acetate, interferon beta), which have roughly similar efficacy (approximately 30 % reduction of clinical relapses). If a patient has breakthrough disease or persistent, unmanageable side effects, transition to a different first-line therapy or escalation to a second-line therapy, such as natalizumab, should be considered. Though the efficacy of second-line agents is higher, the potential risk of serious adverse effects also increases. New therapies, including oral agents, are now being rigorously studied with pediatric clinical trials and may provide safe alternatives for patients that are either unresponsive or intolerant to currently available medications. When necessary, acute exacerbations can be treated with corticosteroids. Intravenous methylprednisolone at a dosage of 30 mg/kg/day (maximum dose 1000 mg/day) for 3–5 days is recommended with severe attacks. If patients are unresponsive to corticosteroids, treatment with either intravenous immunoglobulin or plasma exchange may be required. Fatigue, spasticity, and pain can also occur in pediatric patients with MS. Medications are needed if symptoms are severe and impact quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007;6(9):773–81.

    Article  PubMed  Google Scholar 

  2. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603–13.

    Article  CAS  PubMed  Google Scholar 

  3. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United Sates. Mult Scler. 2009;15(5):627–31.

    Article  CAS  PubMed  Google Scholar 

  4. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset form. Neurology. 2002;59(12):1922–8.

    Article  CAS  PubMed  Google Scholar 

  5. Guilhoto LM, Osorio CA, Machado LR, et al. Pediatric multiple sclerosis report of 14 cases. Brain Dev. 1995;17(1):9–12.

    Article  CAS  PubMed  Google Scholar 

  6. Vergani MI, Reimao R, Silva AM, et al. Multiple sclerosis with early childhood onset. A case report. Arq Neuropsiquiatr. 1988;46(2):195–7.

    Article  CAS  PubMed  Google Scholar 

  7. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54–9.

    PubMed  Google Scholar 

  8. Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005;64(5):891–4.

    Article  PubMed  Google Scholar 

  9. Ghezzi A, Goretti B, Portaccio E, et al. Cognitive impairment in pediatric multiple sclerosis. Neurol Sci. 2010;31 Suppl 2:S215–8.

    Article  CAS  PubMed  Google Scholar 

  10. Charvet LE, O’Donnell EH, Belman AL, et al. Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Mult Scler. 2014 Apr 9.

  11. Julian L, Serafin D, Charvet L, et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013;28(1):102–7.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Wang KC, Lin KH, Lee TC, et al. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions. PLoS One. 2014;9(6):e98192.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011;10(5):436–45. This large prospective study identifies and stratifies risk factors for the development of multiple sclerosis in children.

    Article  CAS  PubMed  Google Scholar 

  15. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67(5):618–24.

    CAS  PubMed  Google Scholar 

  16. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012;5(1):13–22.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Handel AE, Williamson AJ, Disanto G, et al. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One. 2011;6(1):e16149.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Mikaeloff Y, Caridade G, Tardieu M, et al. Parental smoking at home and risk of childhood-onset multiple sclerosis in children. Brain. 2007;130(10):2589–95.

    Article  PubMed  Google Scholar 

  19. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009;73(19):1543–50.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;80(6):548–52.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler. 2012;18(9):1334–6.

    Article  PubMed  Google Scholar 

  22. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247(6):435–42.

    Article  CAS  PubMed  Google Scholar 

  23. Barkhof F, Hommes O, Scheltens P, et al. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991;41(8):1219–22.

    Article  CAS  PubMed  Google Scholar 

  24. Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011;26(6):675–82. This paper describes the practice patterns of physicians in the United States and identifies areas of consensus regarding the treatment and management of children with demyelination.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Ramo-Tello C, Grau-Lopez L, Tintore M, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014;20(6):717–25.

    Article  CAS  PubMed  Google Scholar 

  26. Morrow SA, Stoian CA, Dmitrovic J, et al. The bio-availability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079–80.

    Article  CAS  PubMed  Google Scholar 

  27. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006;46(5):741–53.

    Article  CAS  PubMed  Google Scholar 

  28. Trebst C, Stangel M. Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr Pharm Des. 2006;12(2):241–9.

    Article  CAS  PubMed  Google Scholar 

  29. Sorenson P, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol. 2002;9(6):557–63.

    Article  Google Scholar 

  30. Spalice A, Properzi E, Lo Faro V, et al. Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis. J Child Neurol. 2004;19(8):623–6.

    Article  PubMed  Google Scholar 

  31. Apak R, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 1999;21(4):279–82.

    Article  CAS  PubMed  Google Scholar 

  32. Sahlas D, Miller S, Guerin M, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54(6):1370–2.

    Article  CAS  PubMed  Google Scholar 

  33. Weinshenker B, O’Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–86.

    Article  CAS  PubMed  Google Scholar 

  34. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. The INFB, Group MSS. Interferon beta-1b is effective in realpsing-remiting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–61.

    Article  Google Scholar 

  36. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–94.

    Article  CAS  PubMed  Google Scholar 

  37. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneoulsy in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–504.

    Article  Google Scholar 

  38. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76.

    Article  CAS  PubMed  Google Scholar 

  39. Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Ghezzi A, Amato MP, Capoblanco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420–4.

    Article  CAS  PubMed  Google Scholar 

  41. Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative study. Neurol Sci. 2005;26 Suppl 4:S183–6.

    Article  PubMed  Google Scholar 

  42. Kornek B, Bernert G, Balassy C, et al. Glatirmaer acetate treatment in patients with childhood and juvenille onset multiple sclerosis. Neuropediatrics. 2003;34(3):120–6.

    Article  CAS  PubMed  Google Scholar 

  43. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012;18(7):932–46.

    Article  CAS  PubMed  Google Scholar 

  44. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics. 2013;10(1):2–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139(3):443–6.

    Article  CAS  PubMed  Google Scholar 

  46. Banwell B, Reder AT, Krupp L, et al. Safety and toleratibility of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472–6.

    Article  CAS  PubMed  Google Scholar 

  47. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888–90.

    Article  CAS  PubMed  Google Scholar 

  48. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

    Article  CAS  PubMed  Google Scholar 

  50. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19(8):1106–12. This study describes the safety and efficacy of natalizumab in a large pediatric MS cohort.

    Article  CAS  PubMed  Google Scholar 

  51. Yeh EA, Weinstock-Guttmann B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010;3(5):293–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75(10):912–7.

    Article  CAS  PubMed  Google Scholar 

  53. Huppke P, Stark W, Zurcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65(12):1655–8.

    PubMed  Google Scholar 

  54. Arnal-Garcia C, Garcia-Montero MR, Malaga I, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013;17(1):50–4.

    Article  PubMed  Google Scholar 

  55. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemioogy of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Huppke P, Hummel H, Ellenberger D, et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalance, conversion rate and influence rate on disease severity. Mult Scler. 2014 July 28.

  57. Okuda D. Immunosuppressive treatments in multiple sclerosis. Handbook of Clinical Neurology 2014. p 122.

  58. Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72:2076–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Banwell B, Bar-Or A, Giovannoni G, et al. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol. 2011;7(2):109–22.

    Article  PubMed  Google Scholar 

  60. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477–84.

    Article  CAS  PubMed  Google Scholar 

  61. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.

    Article  CAS  PubMed  Google Scholar 

  62. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014;51:114–8.

    Article  PubMed  Google Scholar 

  63. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Karenfort M, Kieseier BC, Tibussek D, et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol. 2009;51(2):159–61.

    Article  PubMed  Google Scholar 

  65. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence based management strategies for fatigue in multiple sclerosis. Washington: Paralyzed Veterans of America; 1998.

    Google Scholar 

  66. Goretti B, Portaccio E, Ghezzi A, et al. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Mult Scler. 2012;18(3):329–34.

    Article  CAS  PubMed  Google Scholar 

  67. Parrish JB, Weinstock-Guttman B, Smerbeck A, et al. Fatigue and depression in children with demyelinating disorders. J Child Neurol. 2013;28(6):713–8.

    Article  PubMed  Google Scholar 

  68. MacAllister WS, Christodoulou C, Troxell R, et al. Fatigue and quality of life in pediatric multiple sclerosis. Mult Scler. 2009;15(12):1502–8.

    Article  PubMed  Google Scholar 

  69. Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol. 2002;249(8):983–7.

    Article  CAS  PubMed  Google Scholar 

  70. Rammohan KW, Lynn DJ. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;65(12):1995–7.

    PubMed  Google Scholar 

  71. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72(2):179–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;64(7):1139–43.

    Article  CAS  PubMed  Google Scholar 

  73. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 26;74(4):336–43.

  74. Hyser CL, Drake Jr ME. Status epilepticus after baclofen withdrawal. J Natl Med Assoc. 1984;76(5):533. 537–8.

  75. Chawla JM, Sagar R. Baclofen-induced psychosis. Ann Pharmacother. 2006;40(11):2071–3.

    Article  CAS  PubMed  Google Scholar 

  76. Malhotra T, Rosenzweig I. Baclofen withdrawal causes psychosis in otherwise unclouded consciousness. J Neuropsychiatry Clin Neurosci. 2009;21(4):476.

    Article  PubMed  Google Scholar 

  77. Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3(4):250–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Sona Narula, Sarah E. Hopkins, and Brenda Banwell declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Neurology, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, 3501 Civic Center Boulevard, Colket Translational Research Building, 10th floor, Philadelphia, PA, 19104, USA

    Sona Narula MD, Sarah E. Hopkins MD & Brenda Banwell MD

Authors
  1. Sona Narula MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah E. Hopkins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenda Banwell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sona Narula MD.

Additional information

This article is part of the Topical Collection on Pediatric Neurology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narula, S., Hopkins, S.E. & Banwell, B. Treatment of Pediatric Multiple Sclerosis. Curr Treat Options Neurol 17, 10 (2015). https://doi.org/10.1007/s11940-014-0336-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-014-0336-z

Keywords

Search

Navigation